Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Brief Summary: This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). Chemotherapy drugs, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. It is not yet known which combination will work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.


Options:
A: Arm Label: Combination navicixizumab + paclitaxel; Type: EXPERIMENTAL; Interventions: Drug: navicixizumab, Device: Xerna™ TME Panel | Arm Label: Paclitaxel monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Xerna™ TME Panel | Arm Label: Navicixizumab monotherapy; Type: EXPERIMENTAL; Interventions: Drug: navicixizumab, Device: Xerna™ TME Panel | Intervention Type: DRUG; Name: navicixizumab; Assigned to Arm(s): Combination navicixizumab + paclitaxel, Navicixizumab monotherapy | Intervention Type: DEVICE; Name: Xerna™ TME Panel; Assigned to Arm(s): Combination navicixizumab + paclitaxel, Navicixizumab monotherapy, Paclitaxel monotherapy
B: Arm Label: Ixabepilone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ixabepilone | Arm Label: Ixabepilone + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixabepilone, Drug: Bevacizumab | Intervention Type: DRUG; Name: Ixabepilone; Assigned to Arm(s): Ixabepilone, Ixabepilone + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Ixabepilone + Bevacizumab
C: Arm Label: Arm I (PLD, atezolizumab); Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab, Procedure: Computed Tomography, Drug: Pegylated Liposomal Doxorubicin Hydrochloride, Other: Quality-of-Life Assessment | Arm Label: Arm II (PLD, bevacizumab, atezolizumab); Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab, Biological: Bevacizumab, Procedure: Computed Tomography, Drug: Pegylated Liposomal Doxorubicin Hydrochloride, Other: Quality-of-Life Assessment | Arm Label: Arm III (PLD, bevacizumab); Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Procedure: Computed Tomography, Drug: Pegylated Liposomal Doxorubicin Hydrochloride, Other: Quality-of-Life Assessment | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Arm I (PLD, atezolizumab), Arm II (PLD, bevacizumab, atezolizumab) | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): Arm II (PLD, bevacizumab, atezolizumab), Arm III (PLD, bevacizumab) | Intervention Type: PROCEDURE; Name: Computed Tomography; Assigned to Arm(s): Arm I (PLD, atezolizumab), Arm II (PLD, bevacizumab, atezolizumab), Arm III (PLD, bevacizumab) | Intervention Type: DRUG; Name: Pegylated Liposomal Doxorubicin Hydrochloride; Assigned to Arm(s): Arm I (PLD, atezolizumab), Arm II (PLD, bevacizumab, atezolizumab), Arm III (PLD, bevacizumab) | Intervention Type: OTHER; Name: Quality-of-Life Assessment; Assigned to Arm(s): Arm I (PLD, atezolizumab), Arm II (PLD, bevacizumab, atezolizumab), Arm III (PLD, bevacizumab)
D: Arm Label: Bevacizumab combined with Fluzoparib; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: chemotherapy | Arm Label: Bevacizumab combined with chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: chemotherapy | Arm Label: Fluzoparib; Type: EXPERIMENTAL; Interventions: Drug: Fluzoparib | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Bevacizumab combined with Fluzoparib, Bevacizumab combined with chemotherapy | Intervention Type: DRUG; Name: chemotherapy; Assigned to Arm(s): Bevacizumab combined with Fluzoparib, Bevacizumab combined with chemotherapy | Intervention Type: DRUG; Name: Fluzoparib; Assigned to Arm(s): Fluzoparib

Answer: C